CALORIE: Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy
Study Details
Study Description
Brief Summary
Capecitabine is recommended for adjuvant treatment of advanced or metastatic breast cancer and is particularly effective in patients with triple-negative breast cancer (TNBC).
CREATE-X clinical studies have demonstrated that Capecitabine can further improve prognosis and demonstrate good tolerance in patients who have not achieved pathologic complete response (pCR) after neoadjuvant chemotherapy.
Previous studies have confirmed that the pathological features of the low- hormone receptor (HR)positive population in breast cancer are similar to those in the TNBC population, with a poor prognosis and are not sensitive to adjuvant endocrine therapy.
We hypothesize that the use of Capecitabine in breast cancer patients with residual invasive carcinoma after neoadjuvant chemotherapy may improve prognosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The investigators will recruit patients who had low- hormone receptor (HR)positive breast cancer of stage I - IIIC and pathologically assessed residual cancer cells (no pathological complete response, non-pCR) after neoadjuvant chemotherapy with anthracycline, taxane, or both. Participants who have residual components of ductal carcinoma in situ are assessed as having a pathological complete response. Participants with tumor-positive lymph nodes excluded.
Other key eligibility criteria are low- hormone receptor (HR)positive, including low-ER and low-PR, low-ER and PR-negative, low-PR and ER-negative. The definition of low hormone receptor (HR) positive is nuclear staining of 1%-10% of the epithelial component of the tumor.
Eligible participants are centrally enrolled after pathological assessment and are randomly assigned in a 1:1 ratio to receive either capecitabine plus standard therapy or standard therapy alone (control).
The trial treatments are standard postsurgical treatments, which included endocrine therapy in participants with estrogen-receptor-positive (nuclear staining ≥ 1%) disease, targeted therapy in participants with HER-2 overexpression and radiotherapy (if indicated), with or without capecitabine.
After surgery, the capecitabine group receive oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles. The concomitant administration of postsurgical endocrine therapy is allowed. Postsurgical radiotherapy could be given before or after randomization and could be concomitant with postsurgical endocrine therapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Capecitabine The experimental group received oral capecitabine for eight cycles. |
Drug: Capecitabine
Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
|
| Placebo Comparator: Placebo The placebo group received oral placebo for eight cycles. |
Drug: Placebos
Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
|
Outcome Measures
Primary Outcome Measures
- Event Free Survival(DFS) [Time of Surgery up to 5 years.]
First Dose of Capecitabine or Placebo to first documentation of local or distant recurrence, or death or initiation of antineoplastic therapy before documentation of first relapse.
- Overall Survival(OS) [First Dose of Capecitabine or Placebo up to 5 years.]
Time from the first dose of Capecitabine or Placebo to death due to any cause.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Provision of informed consent
-
Women and men at least 18 years of age or older.
-
Pathological confirmation of breast cancer
-
Tumor stage(TNM): T1-4N0-3M0
-
No evidence of distant metastasis
-
Adequate bone marrow, hepatic, and renal function
-
Measurable disease as per RECIST criteria
-
Karnofsky≥70
-
Laboratory criteria:
PLT≥100109/L WBC≥4000/mm3 HGB≥10g/dl ALT and AST<2ULN
Exclusion Criteria:
-
Presence of metastatic disease.
-
Inflammatory breast cancer.
-
Bilateral breast cancer.
-
Postoperative treatment with other adjuvant chemotherapy drugs.
-
Other malignant tumors (concurrent or previous).
-
Pregnant woman.
-
Hypersensitive to any drug in Capecitabine or any ingredient of Capecitabine.
-
Any severe systemic disease contraindicating chemotherapy.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Zhejiang Cancer Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CALORIE